---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-088857"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2026-07-31T00:02:23+00:00"
generated_at: "2026-07-31T10:05:21.535685+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Replimune's RP1 gets favorable FDA advisory committee vote 10-3 for advanced melanoma

## Summary
- FDA advisory committee voted 10 to 3 that efficacy results from IGNYTE study are evaluable and clinically meaningful.
- RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma after anti-PD-1 progression.
- FDA target action date for BLA resubmission is August 2, 2026.
- CEO Sushil Patel expressed gratitude and looks forward to working with FDA.

## SEC filing metadata
- accession: 0001104659-26-088857
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2026-07-31T00:02:23+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465926088857/0001104659-26-088857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465926088857/tm2621708d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-088857
- JSON: https://secwatch.observer/filing/0001104659-26-088857.json
- Plain text: https://secwatch.observer/filing/0001104659-26-088857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.